New oral drug aims to slow Alzheimer's in its earliest stages
NCT ID NCT07027072
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental oral drug called KDS2010 in people with mild cognitive impairment or mild dementia due to Alzheimer's disease. Participants take either a low dose, a higher dose, or a placebo daily for 24 weeks. Researchers measure changes in memory, thinking, and daily living skills, along with blood and spinal fluid biomarkers, to see if the drug can slow disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KDS2010
What this could lead to
If effective, KDS2010 could slow memory loss and daily function decline in early Alzheimer's, offering a new oral treatment option.
What could go wrong
This is an early Phase 2a dose-finding study with only 114 people. It may fail to show benefit or have side effects not yet seen in Phase 1.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT (MCI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ajou University Hospital
RECRUITINGSuwon, Gyeonggi-do, 16499, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Asan Medical Center
RECRUITINGSeoul, Seoul, 05505, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Chonnam National Unversity Hospital
RECRUITINGGwangju, Gwangju, 61469, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Gachon University Gil Medical Center
RECRUITINGIncheon, Incheon, 21565, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hanyang University Guri Hospital
RECRUITINGGuri-si, Gyeonggi-do, 11923, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Hanyang University Seoul Hospital
RECRUITINGSeoul, Seoul, 04763, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Konkuk University Medical Center
RECRUITINGSeoul, Seoul, 05030, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Catholic University of Korea St. Vincent's Hospital
RECRUITINGSuwon, Gyeonggi-do, 16247, South Korea
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••